MAPT and Alzheimer disease: While these earlier studies provided seminal evidence of sex differences in neuropathology, in vivo examination of AD biomarkers has become the gold standard for assessing AD pathology through CSF analysis of Aβ and tau and/or positron emission tomography (PET) radiotracers that detect amyloid (e.g., Pittsburgh Compound‐B [11C‐PiB], 18F‐Florbetapir) and tau (18F‐AV1451) burden in the brain (Leuzy et al., 2019; Maclin, Wang, & Xiao, 2019; Márquez & Yassa, 2019).